Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Rethinking First-Line Immunosuppression for Idiopathic FSGS

Jordana B. Cohen and Jonathan J. Hogan
CJASN March 2016, 11 (3) 372-373; DOI: https://doi.org/10.2215/CJN.00780116
Jordana B. Cohen
Renal, Electrolyte, and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan J. Hogan
Renal, Electrolyte, and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • glomerular disease
  • focal segmental glomerulosclerosis
  • immunosuppression
  • treatment
  • Immune Tolerance

FSGS represents a common histopathologic end point for a diverse group of underlying disease processes (1). These include adaptive and structural changes to the glomeruli, as seen in patients with reflux nephropathy, solitary kidney, low nephron mass, hypertension, and obesity (2), and direct injury to podocytes as occurs with HIV-associated nephropathy, drug exposures, and genetic mutations (2,3). Idiopathic FSGS is diagnosed when a patient presenting with proteinuria (commonly nephrotic range) exhibits FSGS on kidney biopsy, with no clear contributing (i.e., secondary) etiology. This is an important distinction, because it may prompt the use of immunosuppression to attain a remission in proteinuria. Spontaneous remission for patients with idiopathic FSGS and nephrotic-range proteinuria is rare (4), and progression to CKD and ESRD is common for patients who do not experience remission of proteinuria (5). Steroid-resistant FSGS is one of the most challenging glomerular diseases to manage. Although there is evidence that some patients have idiopathic FSGS that is caused by a yet unidentified circulating permeability factor (6–8), it is likely that idiopathic FSGS represents multiple, diverse, and poorly understood pathophysiologic mechanisms.

There is minimal understanding of the mechanisms by which pharmacologic treatments affect disease progression in idiopathic FSGS. The Kidney Disease Improving Global Outcomes practice guidelines for glomerulonephritis recommend renin-angiotensin-aldosterone system blockade, and for patients with nephrotic-range proteinuria, initiation of high–dose glucocorticoid therapy (1 mg/kg daily or 2 mg/kg on alternating days) as first-line therapy (3). Calcineurin inhibitors (CNIs) may be considered in patients with relative contraindications to high-dose steroids (3). These recommendations are primarily on the basis of small retrospective case series (4,9–15), the largest of which comprised 53 patients (10). Although randomized, controlled trials have compared the effectiveness of therapies for steroid-resistant FSGS, data comparing first-line glucocorticoids with other potential first–line therapies are extremely limited (16–18).

In this issue of the Clinical Journal of the American Society of Nephrology, Laurin et al. (19) present an analysis of the largest cohort of patients with idiopathic FSGS to date. Using the Glomerular Disease Collaborative Network (GDCN) Registry, Laurin et al. (19) showed that early treatment with any immunosuppression was associated with significantly greater renal survival compared with no immunosuppression in 458 adults and children with FSGS (hazard ratio, 0.49 for ESRD; 95% confidence interval [95% CI], 0.28 to 0.86). There was no significant difference in renal survival among patients treated with glucocorticoids alone compared with patients treated with CNIs, although there was a trend toward greater survival among patients treated with CNIs.

This study provides important insight into the effects of immunosuppressive therapy on renal outcomes in these patients. It is, by far, the largest observational study evaluating the treatment of idiopathic FSGS with early immunosuppressive therapy. It is the first study of its size to compare renal outcomes between patients treated with early glucocorticoids alone and those treated with early CNI therapy. Perhaps most importantly, the study provides higher-quality evidence than was previously available to support the use of early immunosuppression to prevent ESRD in these patients. Another unique aspect of this study is the light that it sheds on practice patterns. Immunosuppression was prescribed more often in patients with tip lesion FSGS (odds ratio [OR], 3.0; 95% CI, 1.23 to 7.32 versus patients with FSGS not otherwise specified), preserved eGFR (OR, 0.53; 95% CI, 0.29 to 0.99 for eGFR<30 ml/min per 1.73 m2), and hypoalbuminemia (OR, 2.2 for each 1 g/dl lower; 95% CI, 1.59 to 3.13). CNIs were less likely to be prescribed for patients with tip lesion FSGS. Because management was left to the discretion of >600 referring physicians in eight states in the GDCN, these observations likely reflect real life patterns in the treatment of patients with FSGS between 1980 and 2012.

Laurin et al. (19) also used a type of survival analysis that takes into account changes in medication exposure over time, allowing for patients to crossover between treatment groups. The methodology is a practical approach to address a common occurrence in clinical practice that has the potential to heavily bias the results of an observational study. However, the time–varying Cox survival modeling used in the study is also prone to bias. Although the analyses adjusted for factors that were found to be confounders for initial selection of therapy, the effects of confounders that change over time, such as eGFR and proteinuria (i.e., markers of remission), were not addressed, which may play an important role in both changes in therapy and the rate of development of ESRD (20,21). Follow-up proteinuria data, in particular, was often missing (64%). As a result, proteinuria could not be reliably used as an outcome measure; the analyses describing the clinically important outcomes of complete and partial remission were inconclusive. Additionally, the analyses of practice patterns do not take into account changes over time as clinical practice guidelines evolved. Finally, the observed trend toward improved renal survival in patients treated with CNIs compared with glucocorticoids alone requires more intensive, prospective investigation before changing current practice.

The most important limitation for all studies in idiopathic FSGS is that the diagnosis is made on a clinicopathologic basis rather than according to pathogenesis. It is likely that multiple mechanisms are responsible for the development of proteinuria and the FSGS lesion. Although the study by Laurin et al. (19) adds to the epidemiologic data on the management of idiopathic FSGS, the mechanistic role of immunosuppression in the management of idiopathic FSGS remains unclear. As a field, we hope that basic and clinical research in glomerular diseases, including large cohort studies, such as the Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, will lead to the (re)grouping of patients with FSGS on the basis of mechanism and therapeutic implications. The reclassification of idiopathic membranous nephropathy on the basis of anti–phospholipase A2 receptor antibody status is the model that we strive to emulate (22). Until that occurs, the study by Laurin et al. (19) is a much–needed, well designed affirmation of the current management of idiopathic FSGS.

Disclosures

None.

Acknowledgments

J.B.C. is supported by the National Institute of Diabetes and Digesteive and Kidney Diseases of the National Institutes of Health under award number F32DK103484.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS,” on pages 386–394.

  • Copyright © 2016 by the American Society of Nephrology

References

  1. ↵
    1. D’Agati V
    : Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 23: 117–134, 2003
    OpenUrlCrossRefPubMed
  2. ↵
    1. Hogan J,
    2. Radhakrishnan J
    : The treatment of idiopathic focal segmental glomerulosclerosis in adults. Adv Chronic Kidney Dis 21: 434–441, 2014
    OpenUrlCrossRefPubMed
  3. ↵
    KDIGO: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 181–185, 2012
    OpenUrlCrossRefPubMed
  4. ↵
    1. Rydel JJ,
    2. Korbet SM,
    3. Borok RZ,
    4. Schwartz MM
    : Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 25: 534–542, 1995
    OpenUrlCrossRefPubMed
  5. ↵
    1. Troyanov S,
    2. Wall CA,
    3. Miller JA,
    4. Scholey JW,
    5. Cattran DC
    ; Toronto Glomerulonephritis Registry Group: Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 16: 1061–1068, 2005
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Savin VJ,
    2. Sharma R,
    3. Sharma M,
    4. McCarthy ET,
    5. Swan SK,
    6. Ellis E,
    7. Lovell H,
    8. Warady B,
    9. Gunwar S,
    10. Chonko AM,
    11. Artero M,
    12. Vincenti F
    : Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334: 878–883, 1996
    OpenUrlCrossRefPubMed
    1. McCarthy ET,
    2. Sharma M,
    3. Savin VJ
    : Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115–2121, 2010
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Wei C,
    2. El Hindi S,
    3. Li J,
    4. Fornoni A,
    5. Goes N,
    6. Sageshima J,
    7. Maiguel D,
    8. Karumanchi SA,
    9. Yap HK,
    10. Saleem M,
    11. Zhang Q,
    12. Nikolic B,
    13. Chaudhuri A,
    14. Daftarian P,
    15. Salido E,
    16. Torres A,
    17. Salifu M,
    18. Sarwal MM,
    19. Schaefer F,
    20. Morath C,
    21. Schwenger V,
    22. Zeier M,
    23. Gupta V,
    24. Roth D,
    25. Rastaldi MP,
    26. Burke G,
    27. Ruiz P,
    28. Reiser J
    : Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011
    OpenUrlCrossRefPubMed
  8. ↵
    1. Korbet SM,
    2. Schwartz MM,
    3. Lewis EJ
    : The prognosis of focal segmental glomerular sclerosis of adulthood. Medicine (Baltimore) 65: 304–311, 1986
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ponticelli C,
    2. Villa M,
    3. Banfi G,
    4. Cesana B,
    5. Pozzi C,
    6. Pani A,
    7. Passerini P,
    8. Farina M,
    9. Grassi C,
    10. Baroli A
    : Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 34: 618–625, 1999
    OpenUrlCrossRefPubMed
    1. Cattran DC,
    2. Rao P
    : Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32: 72–79, 1998
    OpenUrlCrossRefPubMed
    1. Pei Y,
    2. Cattran D,
    3. Delmore T,
    4. Katz A,
    5. Lang A,
    6. Rance P
    : Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 82: 938–944, 1987
    OpenUrlCrossRefPubMed
    1. Stirling CM,
    2. Mathieson P,
    3. Boulton-Jones JM,
    4. Feehally J,
    5. Jayne D,
    6. Murray HM,
    7. Adu D
    : Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 98: 443–449, 2005
    OpenUrlCrossRefPubMed
    1. Stiles KP,
    2. Abbott KC,
    3. Welch PG,
    4. Yuan CM
    : Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: A retrospective study in a single clinic. Clin Nephrol 56: 89–95, 2001
    OpenUrlPubMed
  10. ↵
    1. Korbet SM
    : Treatment of primary focal segmental glomerulosclerosis. Kidney Int 62: 2301–2310, 2002
    OpenUrlCrossRefPubMed
  11. ↵
    1. Senthil Nayagam L,
    2. Ganguli A,
    3. Rathi M,
    4. Kohli HS,
    5. Gupta KL,
    6. Joshi K,
    7. Sakhuja V,
    8. Jha V
    : Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study. Nephrol Dial Transplant 23: 1926–1930, 2008
    OpenUrlCrossRefPubMed
    1. Goumenos DS,
    2. Tsagalis G,
    3. El Nahas AM,
    4. Shortland JR,
    5. Davlouros P,
    6. Vlachojannis JG,
    7. Brown CB
    : Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: A five-year follow-up study. Nephron Clin Pract 104: c75–c82, 2006
    OpenUrlCrossRefPubMed
  12. ↵
    1. Duncan N,
    2. Dhaygude A,
    3. Owen J,
    4. Cairns TD,
    5. Griffith M,
    6. McLean AG,
    7. Palmer A,
    8. Taube D
    : Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 19: 3062–3067, 2004
    OpenUrlCrossRefPubMed
  13. ↵
    1. Laurin L-P,
    2. Gasim AM,
    3. Poulton CJ,
    4. Hogan SL,
    5. Jennette JC,
    6. Falk RJ,
    7. Foster BJ,
    8. Nachman PG
    : Clin J Am Soc Nephrol 11: 386–394, 2016
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Robins JM,
    2. Hernán MA,
    3. Brumback B
    : Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550–560, 2000
    OpenUrlCrossRefPubMed
  15. ↵
    1. Wehrmann M,
    2. Bohle A,
    3. Held H,
    4. Schumm G,
    5. Kendziorra H,
    6. Pressler H
    : Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 33: 115–122, 1990
    OpenUrlPubMed
  16. ↵
    1. Beck LH Jr..,
    2. Bonegio RG,
    3. Lambeau G,
    4. Beck DM,
    5. Powell DW,
    6. Cummins TD,
    7. Klein JB,
    8. Salant DJ
    : M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21, 2009
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 11 (3)
Clinical Journal of the American Society of Nephrology
Vol. 11, Issue 3
March 07, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Rethinking First-Line Immunosuppression for Idiopathic FSGS
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rethinking First-Line Immunosuppression for Idiopathic FSGS
Jordana B. Cohen, Jonathan J. Hogan
CJASN Mar 2016, 11 (3) 372-373; DOI: 10.2215/CJN.00780116

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Rethinking First-Line Immunosuppression for Idiopathic FSGS
Jordana B. Cohen, Jonathan J. Hogan
CJASN Mar 2016, 11 (3) 372-373; DOI: 10.2215/CJN.00780116
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Telehealth and Kidney Disease Care
  • Time to Abandon Kidney Biopsy to Diagnose Membranous Nephropathy?
  • Should We Let Dialysis Patients Eat Their Fruits and Veggies?
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS
  • PubMed
  • Google Scholar

Keywords

  • glomerular disease
  • focal segmental glomerulosclerosis
  • immunosuppression
  • treatment
  • immune tolerance

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire